SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
4 references·1 citing·22 second hop
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma (2020)Cost–effectiveness analysis of nivolumab …Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma (2018)Cost-effectiveness of nivolum…Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy (2014)Cost-effectiveness analysis o…Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context (2012)Costs of Trastuzumab in Combi…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis (2022)Pembrolizumab Plus Chemothera…Bulletin of the World Health Organization (1955)Cost-Effectiveness in Health and Medicine (1996)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)China's health system and its reform: a review of recent studies (2009)A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer (2013)Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer (2013)Model Parameter Estimation and Uncertainty Analysis (2012)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 (2016)Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma (2019)Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)One Thousand Health-Related Quality-of-Life Estimates (2000)Health state utilities for non small cell lung cancer (2008)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2016)Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2018)Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China (2021)
this work references cited by second hop

References

  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2018Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma120 cited
  • 2014Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy72 cited
  • 2012Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context63 cited

Cited by

  • 2022Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis50 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work